Product nameAnti-CHMP6/VPS20 antibody
See all CHMP6/VPS20 primary antibodies
DescriptionRabbit polyclonal to CHMP6/VPS20
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Cow, Orangutan
Synthetic peptide corresponding to Human CHMP6/VPS20 aa 1-100 (N terminal) conjugated to keyhole limpet haemocyanin.
(Peptide available as
- Recombinant Human CHMP6/VPS20 protein (ab124606) can be used as a positive control in WB. This antibody gave a positive signal in the following whole cell lysates: Hela; Jurkat; HepG2; HEK293; MCF7; JEG3; K562.
This product was previously labelled as CHMP6
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab76929 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 50 kDa (predicted molecular weight: 23 kDa).|
FunctionProbable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. In the ESCRT-III complex, it probably serves as an acceptor for the ESCRT-II complex on endosomal membranes.
Tissue specificityUbiquitously expressed.
Sequence similaritiesBelongs to the SNF7 family.
DomainThe acidic C-terminus and the basic N-termminus are thought to render the protein in a closed, soluble and inactive conformation through an autoinhibitory intramolecular interaction. The open and active conformation, which enables membrane binding and oligomerization, is achieved by interaction with other cellular binding partners, probably including other ESCRT components.
Cellular localizationEndomembrane system. Endosome membrane. Late endosome membrane. Localizes to endosomal membranes.
- Information by UniProt
- Charged multivesicular body protein 6 antibody
- chmp6 antibody
- CHMP6_HUMAN antibody
All lanes : Anti-CHMP6/VPS20 antibody (ab76929) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lane 4 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate
Lane 5 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
Lane 6 : JEG-3 (Human placental choriocarcinoma cell line) Whole Cell Lysate
Lane 7 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 23 kDa
Observed band size: 50 kDa why is the actual band size different from the predicted?
Exposure time: 30 seconds
This protein contains a N-myristoyl glycine amino acid modification that we believe might be responsible for the size shift observed. Furthermore, the 50 kDa band observed is comparable to the molecular weight shown in scientific literature and obtained with other commercially available antibodies to CHMP6/VPS20. Abcam would love to hear from anyone that can help explain the results obtained.
ab76929 has not yet been referenced specifically in any publications.